INR 99.07
(8.0%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | 1.11 Billion INR | -45.64% |
2022 | 403.32 Million INR | 6.62% |
2021 | 139.29 Million INR | 432.48% |
2020 | 110.68 Million INR | -80.55% |
2019 | 963.92 Million INR | 104.53% |
2018 | 473.02 Million INR | 19.94% |
2017 | 479.51 Million INR | 6.78% |
2016 | 317.18 Million INR | 13.88% |
2015 | 61.67 Million INR | 4.49% |
2014 | 96.03 Million INR | -30.55% |
2013 | 286.42 Million INR | 160.1% |
2012 | 168.25 Million INR | -92.6% |
2011 | 28.41 Million INR | 3639.83% |
2010 | 12.73 Million INR | -96.8% |
2009 | 1.89 Billion INR | 99.92% |
2008 | 2.08 Billion INR | -47.28% |
2007 | 1.8 Billion INR | 23.52% |
2006 | 1.45 Billion INR | 20.68% |
2005 | 1.2 Billion INR | 29.47% |
2004 | 933.92 Million INR | 7.86% |
2003 | 865.84 Million INR | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q1 | 204 Million INR | -22.11% |
2023 Q1 | 135.1 Million INR | 177.98% |
2023 FY | - INR | -45.64% |
2023 Q2 | 580.2 Million INR | 329.46% |
2023 Q3 | 139.1 Million INR | -76.03% |
2023 Q4 | 241.5 Million INR | 73.62% |
2022 Q4 | 48.6 Million INR | -62.27% |
2022 Q1 | 61.2 Million INR | -16.39% |
2022 Q2 | 701.2 Million INR | 1045.75% |
2022 Q3 | 128.8 Million INR | -81.63% |
2022 FY | - INR | 6.62% |
2021 FY | - INR | 432.48% |
2021 Q4 | 73.19 Million INR | 31.88% |
2021 Q3 | 55.5 Million INR | -93.41% |
2021 Q2 | 842 Million INR | 1294.04% |
2021 Q1 | 60.4 Million INR | 5.72% |
2020 Q2 | 51.6 Million INR | 44.94% |
2020 Q3 | 69.2 Million INR | 34.11% |
2020 FY | - INR | -80.55% |
2020 Q4 | 57.13 Million INR | -17.44% |
2020 Q1 | 35.6 Million INR | -93.71% |
2019 Q3 | 19.4 Million INR | -94.49% |
2019 Q2 | 352.4 Million INR | 1119.38% |
2019 Q4 | 566.1 Million INR | 2818.06% |
2019 FY | - INR | 104.53% |
2019 Q1 | 28.9 Million INR | 5.54% |
2018 Q3 | 46.6 Million INR | -84.75% |
2018 Q2 | 305.5 Million INR | 220.23% |
2018 Q1 | 95.4 Million INR | 197.2% |
2018 FY | - INR | 19.94% |
2018 Q4 | 27.38 Million INR | -41.24% |
2017 FY | - INR | 6.78% |
2017 Q4 | 32.1 Million INR | 0.0% |
2016 Q4 | 45.3 Million INR | 0.0% |
2016 FY | - INR | 13.88% |
2015 Q3 | 7.6 Million INR | -92.6% |
2015 Q2 | 102.7 Million INR | 123.26% |
2015 Q1 | 46 Million INR | -77.68% |
2015 FY | - INR | 4.49% |
2015 Q4 | 6.2 Million INR | -18.42% |
2014 FY | - INR | -30.55% |
2014 Q2 | 217.3 Million INR | 247.12% |
2014 Q3 | -11.1 Million INR | -105.11% |
2014 Q4 | 206.1 Million INR | 1956.77% |
2014 Q1 | 62.6 Million INR | 60.91% |
2013 Q1 | 106.3 Million INR | 808.95% |
2013 Q4 | 38.9 Million INR | -15.06% |
2013 Q3 | 45.8 Million INR | -81.38% |
2013 Q2 | 246 Million INR | 131.42% |
2013 FY | - INR | 160.1% |
2012 Q3 | 140.2 Million INR | 168.58% |
2012 Q4 | -14.99 Million INR | -110.69% |
2012 FY | - INR | -92.6% |
2012 Q1 | -9.3 Million INR | -100.42% |
2012 Q2 | 52.2 Million INR | 661.29% |
2011 Q3 | -6.7 Million INR | 0.0% |
2011 FY | - INR | 3639.83% |
2011 Q4 | 2.22 Billion INR | 33361.79% |
2010 FY | - INR | -96.8% |
2009 FY | - INR | 99.92% |
2008 Q4 | 147.6 Million INR | 0.0% |
2008 FY | - INR | -47.28% |
2007 FY | - INR | 23.52% |
2006 FY | - INR | 20.68% |
2005 FY | - INR | 29.47% |
2004 FY | - INR | 7.86% |
2003 FY | - INR | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
Eris Lifesciences Limited | 6.98 Billion INR | 84.021% |
Shilpa Medicare Limited | 2.58 Billion INR | 56.864% |
Solara Active Pharma Sciences Limited | -2.82 Billion INR | 139.56% |
J. B. Chemicals & Pharmaceuticals Limited | 9.33 Billion INR | 88.041% |
Aarey Drugs & Pharmaceuticals Limited | 45.16 Million INR | -2371.693% |
Aarti Pharmalabs Limited | 3.9 Billion INR | 71.445% |
Alkem Laboratories Limited | 24.19 Billion INR | 95.386% |
Alembic Pharmaceuticals Limited | 9.61 Billion INR | 88.392% |
AstraZeneca Pharma India Limited | 2.35 Billion INR | 52.633% |
Divi's Laboratories Limited | 25.43 Billion INR | 95.61% |
Bafna Pharmaceuticals Limited | 114.58 Million INR | -874.263% |
Bal Pharma Limited | 345.59 Million INR | -223.023% |
Aurobindo Pharma Limited | 61.78 Billion INR | 98.193% |
Bliss GVS Pharma Limited | 1.47 Billion INR | 24.522% |
Brooks Laboratories Limited | 41.72 Million INR | -2575.278% |
FDC Limited | 3.38 Billion INR | 67.025% |
Granules India Limited | 8.6 Billion INR | 87.025% |
Hester Biosciences Limited | 539.47 Million INR | -106.933% |
Ind-Swift Limited | 1.06 Billion INR | -4.814% |
Ipca Laboratories Limited | 13.29 Billion INR | 91.606% |
Jagsonpal Pharmaceuticals Limited | 323.46 Million INR | -245.125% |
Jubilant Pharmova Limited | 8 Billion INR | 86.056% |
Laurus Labs Limited | 8 Billion INR | 86.056% |
Medico Remedies Limited | 129.09 Million INR | -764.75% |
Morepen Laboratories Limited | 1.72 Billion INR | 35.32% |
Orchid Pharma Limited | 1.41 Billion INR | 21.339% |
Vaishali Pharma Limited | 31.71 Million INR | -3420.356% |
Sequent Scientific Limited | 549.8 Million INR | -103.045% |
Sigachi Industries Limited | 883.39 Million INR | -26.369% |
Suven Pharmaceuticals Limited | 4.67 Billion INR | 76.132% |
Valiant Laboratories Limited | 12.73 Million INR | -8663.168% |
Windlas Biotech Limited | 781.72 Million INR | -42.806% |
ZIM Laboratories Limited | 462.09 Million INR | -141.581% |
Zydus Lifesciences Limited | 56.22 Billion INR | 98.014% |
Aarti Drugs Limited | 3.24 Billion INR | 65.637% |
Ajanta Pharma Limited | 12.56 Billion INR | 91.116% |
Amrutanjan Health Care Limited | 681.59 Million INR | -63.783% |
Bajaj HealthCare Limited | 406.23 Million INR | -174.8% |
Biofil Chemicals and Pharmaceuticals Limited | 12.99 Million INR | -8489.874% |
Caplin Point Laboratories Limited | 6.18 Billion INR | 81.947% |
Dr. Reddy's Laboratories Limited | 88.27 Billion INR | 98.735% |
Glenmark Life Sciences Limited | 6.86 Billion INR | 83.734% |
Hikal Limited | 2.69 Billion INR | 58.535% |
Ind-Swift Laboratories Limited | 6.86 Billion INR | 83.731% |
Kilitch Drugs (India) Limited | 287.42 Million INR | -288.393% |
Mangalam Drugs & Organics Limited | 174.94 Million INR | -538.105% |
Medicamen Biotech Limited | 245.66 Million INR | -354.425% |
Nectar Lifesciences Limited | 1.53 Billion INR | 27.302% |
Neuland Laboratories Limited | 4.74 Billion INR | 76.489% |
Par Drugs and Chemicals Limited | 228.17 Million INR | -389.249% |
RPG Life Sciences Limited | 1.28 Billion INR | 12.888% |
Unichem Laboratories Limited | 742.35 Million INR | -50.378% |
Venus Remedies Limited | 711.8 Million INR | -56.833% |
Wanbury Limited | 985.49 Million INR | -13.278% |
Wockhardt Limited | 1.08 Billion INR | -3.365% |
Innova Captab Limited | 1.66 Billion INR | 33.086% |
Procter & Gamble Health Limited | 3.07 Billion INR | 63.689% |
Themis Medicare Limited | 562.6 Million INR | -98.423% |
IOL Chemicals and Pharmaceuticals Limited | 2.6 Billion INR | 57.173% |
Mankind Pharma Limited | 28.09 Billion INR | 96.027% |
Glenmark Pharmaceuticals Limited | 11.34 Billion INR | 90.159% |
Sakar Healthcare Limited | 393.26 Million INR | -183.862% |
Albert David Limited | 1.04 Billion INR | -6.784% |
Lupin Limited | 36.96 Billion INR | 96.98% |
Gufic Biosciences Limited | 1.48 Billion INR | 24.596% |
Sun Pharmaceutical Industries Limited | 138.36 Billion INR | 99.193% |
Lincoln Pharmaceuticals Limited | 1.34 Billion INR | 16.897% |
Syncom Formulations (India) Limited | 430.27 Million INR | -159.447% |
Piramal Enterprises Limited | -3.86 Billion INR | 128.912% |
Torrent Pharmaceuticals Limited | 35 Billion INR | 96.811% |
NATCO Pharma Limited | 18.79 Billion INR | 94.06% |
Suven Life Sciences Limited | -992.78 Million INR | 212.446% |
Krebs Biochemicals & Industries Limited | -82.72 Million INR | 1449.426% |
Strides Pharma Science Limited | 3.76 Billion INR | 70.347% |
Indoco Remedies Limited | 2.64 Billion INR | 57.827% |
Alpa Laboratories Limited | 229.96 Million INR | -385.448% |
Lasa Supergenerics Limited | -65.08 Million INR | 1815.335% |
Sun Pharma Advanced Research Company Limited | -3.73 Billion INR | 129.917% |